RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial.

Most women with estrogen receptor expressing breast cancers receiving anti-estrogens such as tamoxifen may not need or benefit from them. Besides the estrogen receptor, there are no predictive biomarkers to help select breast cancer patients for tamoxifen treatment. CCND1 (cyclin D1) gene amplificat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dana Keilty, Marguerite Buchanan, Katerina Ntapolias, Olga Aleynikova, Dongsheng Tu, Xiao Li, Lois Shepherd, Vivien Bramwell, Mark Basik
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science (PLoS) 2013-01-01
Colecção:PLoS ONE
Acesso em linha:http://europepmc.org/articles/PMC3868649?pdf=render
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados